Patents by Inventor Martine Latta

Martine Latta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7033826
    Abstract: A recombinant adenovirus in which the expression of a nucleic acid sequence coding for at least one homologous or heterologous gene of viral origin is placed under the control of an inducible promoter, is disclosed. The use of such recombinant adenoviruses for preparing AAVs, and a complementary cell line and preparation method therefor, are also disclosed. Furthermore, pharmaceutical compositions containing such an adenovirus are disclosed.
    Type: Grant
    Filed: April 15, 2002
    Date of Patent: April 25, 2006
    Assignee: Aventis Pharma S.A.
    Inventors: Michel Perricaudet, Martine Latta, Edouard Prost, Patrice Yeh, Cécile Orsini, Emmanuelle Vigne
  • Publication number: 20060002893
    Abstract: Modification of internal sites of the adenovirus fiber protein and hexon protein permit effective targeting of adenovirus vectors. Accessible sites to redirect adenovirus targeting were identified. The HVR5 loop of the hexon protein and the HI loop of the fiber protein (knob) were highly permissive for the insertion of foreign protein sequences, which apparently did not impact on the viability and productivity of corresponding viruses. Accessibility and functionality of the epitope strongly depend on the size of the neighboring spacers. Other results suggest that short targeting peptides can be effectively fused to the C-terminus of the fiber protein. In a specific embodiment, a series of adenovirus vectors modified at the HVR5 site, the fiber protein HI loop, or the fiber protein C-terminus to target urokinase-type plasminogen activator receptor bearing cells were prepared. Such vectors are particularly useful for targeting the vasculature, e.g., for gene therapy of cancers or cardiovascular conditions.
    Type: Application
    Filed: January 20, 2005
    Publication date: January 5, 2006
    Inventors: Emmanuelle Vigne, Jean-Francois Dedieu, Martine Latta, Patrice Yeh, Michel Perricaudet
  • Patent number: 6911199
    Abstract: Modification of internal sites of the adenovirus fiber protein and hexon protein permit effective targeting of adenovirus vectors. Accessible sites to redirect adenovirus targeting were identified. The HVR5 loop of the hexon protein and the HI loop of the fiber protein (knob) were highly permissive for the insertion of foreign protein sequences, which apparently did not impact on the viability and productivity of corresponding viruses. Accessibility and functionality of the epitope strongly depend on the size of the neighboring spacers. Other results suggest that short targeting peptides can be effectively fused to the C-terminus of the fiber protein. In a specific embodiment, a series of adenovirus vectors modified at the HVR5 site, the fiber protein HI loop, or the fiber protein C-terminus to target urokinase-type plasminogen activator receptor bearing cells were prepared. Such vectors are particularly useful for targeting the vasculature, e.g., for gene therapy of cancers or cardiovascular conditions.
    Type: Grant
    Filed: February 22, 2001
    Date of Patent: June 28, 2005
    Assignee: Aventis Pharma S.A.
    Inventors: Emmanuelle Vigne, Jean-Francois Dedieu, Martine Latta, Patrice Yeh, Michel Perricaudet
  • Publication number: 20030143209
    Abstract: Modification of internal sites of the adenovirus fiber protein and hexon protein permit effective targeting of adenovirus vectors. Accessible sites to redirect adenovirus targeting were identified. The HVR5 loop of the hexon protein and the HI loop of the fiber protein (knob) were highly permissive for the insertion of foreign protein sequences, which apparently did not impact on the viability and productivity of corresponding viruses. Accessibility and functionality of the epitope strongly depend on the size of the neighboring spacers. Other results suggest that short targeting peptides can be effectively fused to the C-terminus of the fiber protein. In a specific embodiment, a series of adenovirus vectors modified at the HVR5 site, the fiber protein HI loop, or the fiber protein C-terminus to target urokinase-type plasminogen activator receptor bearing cells were prepared. Such vectors are particularly useful for targeting the vasculature, e.g. for gene therapy of cancers or cardiovascular conditions.
    Type: Application
    Filed: February 22, 2001
    Publication date: July 31, 2003
    Inventors: Emmanuelle Vigne, Jean-Francois Dedieu, Martine Latta, Patrice Yeh, Michel Perricaudet
  • Publication number: 20030039634
    Abstract: A recombinant adenovirus in which the expression of a nucleic acid sequence coding for at least one homologous or heterologous gene of viral origin is placed under the control of an inducible promoter, is disclosed. The use of such recombinant adenoviruses for preparing AAVs, and a complementary cell line and preparation method therefor, are also disclosed. Furthermore, pharmaceutical compositions containing such an adenovirus are disclosed.
    Type: Application
    Filed: April 15, 2002
    Publication date: February 27, 2003
    Inventors: Michel Perricaudet, Martine Latta, Edouard Prost, Patrice Yeh, Cecile Orsini, Emmanuelle Vigne
  • Publication number: 20020098165
    Abstract: A recombinant adenovirus in which the expression of a nucleic acid sequence coding for at least one homologous or heterologous gene of viral origin is placed under the control of an inducible promoter, is disclosed. The use of such recombinant adenoviruses for preparing AAVs, and a complementary cell line and preparation method therefor, are also disclosed. Furthermore, pharmaceutical compositions containing such an adenovirus are disclosed.
    Type: Application
    Filed: December 19, 1997
    Publication date: July 25, 2002
    Applicant: Rhone-Poulenc S.A.
    Inventors: MICHEL PERRICAUDET, MARTINE LATTA, EDOUARD PROST, PATRICE YEH, CECILE ORSINI, EMMANUELLE VIGNE
  • Patent number: 6420170
    Abstract: A recombinant adenovirus in which the expression of a nucleic acid sequence coding for at least one homologous or heterologous gene of viral origin is placed under the control of an inducible promoter, is disclosed. The use of such recombinant adenoviruses for preparing AAVs, and a complementary cell line and preparation method therefor, are also disclosed. Furthermore, pharmaceutical compositions containing such an adenovirus are disclosed.
    Type: Grant
    Filed: December 19, 1997
    Date of Patent: July 16, 2002
    Assignee: Aventis Pharma S.A.
    Inventors: Michel Perricaudet, Martine Latta, Edouard Prost, Patrice Yeh, Cécile Orsini, Emmanuelle Vigne
  • Publication number: 20010014319
    Abstract: Defective recombinant viruses containing an inserted gene coding for all or part of lecithin-cholesterol acyltransferase (LCAT) or a variant thereof, pharmaceutical compositions containing said viruses, and the use thereof for treating or preventing dyslipoproteinaemia-related diseases, are disclosed.
    Type: Application
    Filed: November 5, 1997
    Publication date: August 16, 2001
    Applicant: RHONE-POULENC RORER S.A.
    Inventors: PATRICE DENEFLE, NICOLAS DUVERGER, MARTINE LATTA-MAHIEU, SANDRINE SEGURET
  • Patent number: 6127175
    Abstract: The invention relates to cells usable for the production of defective adenoviruses comprising, inserted into their genome, a portion of the region E4 of an adenovirus genome carrying the reading phase ORF6 under the control of a functional promoter.
    Type: Grant
    Filed: July 17, 1997
    Date of Patent: October 3, 2000
    Assignee: Rhone-Poulenc Rorer S.A.
    Inventors: Emmanuelle Vigne, Michel Perricaudet, Jean-Fran.cedilla.ois Dedieu, Cecile Orsini, Patrice Yeh, Martine Latta, Edouard Prost
  • Patent number: 6033885
    Abstract: The present invention relates to recombinant adenoviruses having a cassette capable of integrating into the genome of infected cells, their preparation, pharmaceutical compositions containing them, and their use. In particular, the cassette contains at least one inverted terminal repeat (ITR) Sequence from AAV and a heterologous DNA Sequence.
    Type: Grant
    Filed: September 12, 1996
    Date of Patent: March 7, 2000
    Assignee: Rhone-Poulenc Rorer S.A.
    Inventors: Martine Latta, Patrice Denefle, Emmanuelle Vigne, Michel Perricaudet
  • Patent number: 5187261
    Abstract: Mature human serum albumin is produced from a human serum albumin produced by a microbiological route in the form of fused protein ("pseudo-pro-HSA") containing an N-terminal peptide elongation.
    Type: Grant
    Filed: February 8, 1991
    Date of Patent: February 16, 1993
    Assignee: Genetica
    Inventors: Martine Latta, Jean-Francois Mayaux, Paolo Sarmientos
  • Patent number: 5100784
    Abstract: Mature human serum albumin is produced from a human serum albumin produced by a microbiological route in the form of fused protein ("pseudo-pro-HSA") containing an N-terminal peptide elongation.
    Type: Grant
    Filed: February 19, 1987
    Date of Patent: March 31, 1992
    Assignee: Genetica
    Inventors: Martine Latta, Jean-Francois Mayaux, Paolo Sarmientos
  • Patent number: 4914027
    Abstract: Human serum albumin is produced by culturing a bacterium (e.g. E. coli) capable of maintaining a plasmid containing an inducible promoter (e.g. P.sub.trp) upstream of the penicillin amidase promoter, the ribosome binding site of the penicillin amidase gene and the penicillin amidase signal peptide, fused with the structural gene for human serum albumin.
    Type: Grant
    Filed: March 25, 1986
    Date of Patent: April 3, 1990
    Assignee: Genetica
    Inventors: Michael Knapp, Georges Brefort, Martine Latta, Jean-Francois Mayaux, Paolo Sarmientos